videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Ascelia Pharma

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 19 May at 10:00 AM when she presents the results for the first quarter of 2025.

<section id="vs-about-section" class="about widgets ng-scope">
<div class="container">
<div class="content">
<div class="intro">
<p><strong>You can already now sign up for the event and send in your questions. You don&#x2019;t have to participate live to submit questions for the event.</strong><br><br>Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 19 May at 10:00 AM when she presents the results for the first quarter of 2025.<br><br>During the quarter, Ascelia Pharma announced a positive outcome from its meeting with the FDA and confirmed its plan to submit the NDA for Orviglance in mid-2025. The company also determined the subscription price for warrant TO1 at SEK 2.15. Following the end of the quarter, Ascelia Pharma announced a subscription rate of approximately 96% for warrant TO1, resulting in gross proceeds of SEK 43 million.<br><br>Ascelia Pharma is a biotech company focused on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates &#x2013; Orviglance&#xae; (Mangoral) and Oncoral &#x2013; in clinical development. Ascelia Pharma has its global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)<br><br></p>
<p><strong>Disclaimer:</strong> HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup, 12.30, 23 April 2025.</p>
</div>
</div>
</div>
</section>

HC Andersen Capital

Ascelia Pharma - First quarter 2025 highlights

Mariannen Makrokatsaus | Sijoittaja 2025

Lassila & Tikanoja

Lassila & Tikanoja ylimääräinen yhtiökokous 2025

UPM-Kymmene

UPM ja Sappi suunnittelevat graafisten paperien yhteisyritystä

GreenMobility

GreenMobility: How far away are driverless cars in Denmark

Outokumpu

Outokumpu sijoituskohteena | Sijoittajapäivä 24.11.2025

Viimeisimmät videot